Lior Ungar, Rotem Hershkovitch, Uzi Nissim, Roberto Spiegelmann
Department of Neurological Surgery, The Charles Clore Hospitalization Tower, West Wing Sheba Medical Center, Ramat Gan, Israel.
Chaim Sheba Medical Center, 52621 Tel HaShomer, Ramat Gan, Israel.
Acta Neurochir (Wien). 2020 Apr;162(4):839-844. doi: 10.1007/s00701-020-04251-7. Epub 2020 Feb 11.
Glomus jugulare tumors (GJTs) are uncommon and locally disruptive tumors that usually arise within the jugular foramen of the temporal bone. Surgery was the treatment of choice up until recently. In the last decades, however, radiosurgery has surfaced as a promising alternative treatment by providing excellent tumor control with low risk of cranial nerve injuries. Our aim was to examine the results of radiosurgery specifically, linear accelerator stereotactic radiosurgery (LINAC SRS) for GJT treatment. We hypothesized that radiosurgery will reduce the size of the tumor and improve neurological symptoms.
Between January 1, 1994 and December 31, 2013, 30 patients with GJTs were treated in Sheba Medical Center using LINAC SRS treatment. Comprehensive clinical follow-up was available for 23 patients. Sixteen patients were female and seven males with a median age of 64 years, with a range of 18-87 years. In 19 of the patients, LINAC SRS was the primary treatment, whereas in the remaining four cases, surgery or embolization preceded radiosurgery. The median treated dose to tumor margin was 14 Gy (range 12-27 Gy), and the median tumor volume before treatment was 5 ml (range 0.5-15 ml).
Following the LINAC SRS treatment, 14 of 23 patients (60%) showed improvement of previous neurological deficits, nine patients (40%) remained unchanged. At the end of a follow-up, tumor reduction was seen in 13 patients and a stable volume in eight (91% tumor control rate). Two cases of tumor progression were noted. Three patients (13%) had post- SRS complications during the follow-up, two of which achieved tumor control, while in one the tumor advanced.
LINAC SRS is a practical treatment option for GJTs, with a high rate of tumor control and satisfactory neurological improvement.
颈静脉球瘤(GJT)是一种罕见的、具有局部破坏性的肿瘤,通常起源于颞骨的颈静脉孔。直到最近,手术一直是首选的治疗方法。然而,在过去几十年中,放射外科作为一种有前景的替代治疗方法出现,它能以较低的脑神经损伤风险实现良好的肿瘤控制。我们的目的是具体研究放射外科,即直线加速器立体定向放射外科(LINAC SRS)治疗GJT的效果。我们假设放射外科将缩小肿瘤大小并改善神经症状。
1994年1月1日至2013年12月31日期间,谢巴医疗中心使用LINAC SRS治疗了30例GJT患者。对23例患者进行了全面的临床随访。16例为女性,7例为男性,中位年龄64岁,年龄范围为18 - 87岁。19例患者中,LINAC SRS是主要治疗方法,而在其余4例中,放射外科之前进行了手术或栓塞治疗。肿瘤边缘的中位治疗剂量为14 Gy(范围12 - 27 Gy),治疗前的中位肿瘤体积为5 ml(范围0.5 - 15 ml)。
LINAC SRS治疗后,23例患者中有14例(60%)先前的神经功能缺损得到改善,9例(40%)保持不变。随访结束时,13例患者肿瘤缩小,8例患者肿瘤体积稳定(肿瘤控制率为91%)。记录到2例肿瘤进展。3例患者(13%)在随访期间出现放射外科治疗后并发症,其中2例实现了肿瘤控制,而1例肿瘤进展。
LINAC SRS是治疗GJT的一种实用选择,具有较高的肿瘤控制率和令人满意的神经功能改善效果。